When you enter multiple keywords separated by space, your search will contain results that match any of the keywords (OR search).
  • 46 Hits
  • Search Condition : Filter (MeSH = Carcinoma, Non-Small-Cell Lung / drug therapy*)
Species Resource Title
Human and Animal Cells EBC-1(RCB1965) Selective beta2-adrenoceptor agonist enhances sensitivity to cisplatin in non-small cell lung cancer cell line.
Human and Animal Cells II-18(RCB2093) , PC-14(RCB0446) , RERF-LC-KJ(RCB1313) Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines.
Human and Animal Cells LC-2/ad(RCB0440) HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Human and Animal Cells Ba/F3(RCB0805) Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation.
Human and Animal Cells PC-9(RCB4455) A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells.
Human and Animal Cells A549(RCB0098) Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells.
Human and Animal Cells PC-9(RCB4455) Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC.
Human and Animal Cells PC-9(RCB4455) Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Human and Animal Cells PC-9(RCB4455) Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Human and Animal Cells PC-9(RCB4455) Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
Human and Animal Cells A549(RCB0098) Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin.
Human and Animal Cells KP4(RCB1005) Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Human and Animal Cells PC-9(RCB4455) Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Human and Animal Cells PC-9(RCB4455) ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
Human and Animal Cells LK-2(RCB1970) , RERF-LC-AI(RCB0444) , EBC-1(RCB1965) , LC-1/sq-SF(RCB0438) Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.
Human and Animal Cells A549(RCB0098) Interleukin-6 blockade attenuates lung cancer tissue construction integrated by cancer stem cells.
Human and Animal Cells PC-9(RCB4455) Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
Human and Animal Cells KP4(RCB1005) Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.
Human and Animal Cells LC-2/ad(RCB0440) Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells.
Human and Animal Cells A549(RCB0098) , WI-38(RCB0702) p53-independent structure-activity relationships of 3-ring mesogenic compounds' activity as cytotoxic effects against human non-small cell lung cancer lines.